Alvydas Česas

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

Claus Bolling, T. Graefe, C. Lübbing et al. · Investigational New Drugs · 2006 · 77 citations

Urology, Medicine, Phase Ii Study +6

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations

Breast Oncology, Medicine, Primary Analysis +7

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

Victoria Atkinson, Shahneen Sandhu, Geke A.P. Hospers et al. · Melanoma Research · 2020 · 35 citations · Full text

Oncology, Melanoma, Pharmacology +12

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

Tamás Pintér, Zandra Klippel, Alvydas Česas et al. · Clinical Colorectal Cancer · 2016 · 28 citations

Gastrointestinal Oncology, Medicine, Phase Iii +10